|
1
|
Bourguignon LY: CD44-mediated oncogenic
signaling and cytoskeleton activation during mammary tumor
progression. J Mammary Gland Biol Neoplasia. 6:287–297. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zoller M: CD44: can a cancer-initiating
cell profit from an abundantly expressed molecule? Nat Rev Cancer.
11:254–267. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marhaba R and Zoller M: CD44 in cancer
progression: adhesion, migration and growth regulation. J Mol
Histol. 35:211–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herrlich P, Morrison H, Sleeman J, et al:
CD44 acts both as a growth- and invasiveness-promoting molecule and
as a tumor-suppressing cofactor. Ann NY Acad Sci. 910:106–120.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Screaton GR, Bell MV, Bell JI and Jackson
DG: The identification of a new alternative exon with highly
restricted tissue expression in transcripts encoding the mouse
Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons
between mouse, human, and rat. J Biol Chem. 268:12235–12238.
1993.
|
|
6
|
Herrera-Gayol A and Jothy S: Adhesion
proteins in the biology of breast cancer: contribution of CD44. Exp
Mol Pathol. 66:149–156. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gunthert U, Hofmann M, Rudy W, et al: A
new variant of glycoprotein CD44 confers metastatic potential to
rat carcinoma cells. Cell. 65:13–24. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rudy W, Hofmann M, Schwartz-Albiez R, et
al: The two major CD44 proteins expressed on a metastatic rat tumor
cell line are derived from different splice variants: each one
individually suffices to confer metastatic behavior. Cancer Res.
53:1262–1268. 1993.PubMed/NCBI
|
|
9
|
Kaufmann M, Heider KH, Sinn HP, von
Minckwitz G, Ponta H and Herrlich P: CD44 variant exon epitopes in
primary breast cancer and length of survival. Lancet. 345:615–619.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tempfer C, Losch A, Heinzl H, et al:
Prognostic value of immunohistochemically detected CD44 isoforms
CD44v5, CD44v6 and CD44v7–8 in human breast cancer. Eur J Cancer.
32A:2023–2025. 1996.
|
|
11
|
Sinn HP, Heider KH, Skroch-Angel P, et al:
Human mammary carcinomas express homologues of rat
metastasis-associated variants of CD44. Breast Cancer Res Treat.
36:307–313. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reber S, Matzku S, Gunthert U, Ponta H,
Herrlich P and Zoller M: Retardation of metastatic tumor growth
after immunization with metastasis-specific monoclonal antibodies.
Int J Cancer. 46:919–927. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seiter S, Arch R, Reber S, et al:
Prevention of tumor metastasis formation by anti-variant CD44. J
Exp Med. 177:443–455. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Orian-Rousseau V, Chen L, Sleeman JP,
Herrlich P and Ponta H: CD44 is required for two consecutive steps
in HGF/c-Met signaling. Genes Dev. 16:3074–3086. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Recio JA and Merlino G: Hepatocyte growth
factor/scatter factor induces feedback up-regulation of CD44v6 in
melanoma cells through Egr-1. Cancer Res. 63:1576–1582.
2003.PubMed/NCBI
|
|
16
|
Cheng C, Yaffe MB and Sharp PA: A positive
feedback loop couples Ras activation and CD44 alternative splicing.
Genes Dev. 20:1715–1720. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsukita S, Oishi K, Sato N, Sagara J and
Kawai A: ERM family members as molecular linkers between the cell
surface glycoprotein CD44 and actin-based cytoskeletons. J Cell
Biol. 126:391–401. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Legg JW and Isacke CM: Identification and
functional analysis of the ezrin-binding site in the hyaluronan
receptor, CD44. Curr Biol. 8:705–708. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yonemura S, Hirao M, Doi Y, Takahashi N,
Kondo T and Tsukita S: Ezrin/radixin/moesin (ERM) proteins bind to
a positively charged amino acid cluster in the juxta-membrane
cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol.
140:885–895. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wahl MC, Will CL and Luhrmann R: The
spliceosome: design principles of a dynamic RNP machine. Cell.
136:701–718. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cooper TA, Wan L and Dreyfuss G: RNA and
disease. Cell. 136:777–793. 2009. View Article : Google Scholar
|
|
22
|
Xu Q and Lee C: Discovery of novel splice
forms and functional analysis of cancer-specific alternative
splicing in human expressed sequences. Nucleic Acids Res.
31:5635–5643. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim E, Goren A and Ast G: Insights into
the connection between cancer and alternative splicing. Trends
Genet. 24:7–10. 2008. View Article : Google Scholar
|
|
24
|
Venables JP, Klinck R, Bramard A, et al:
Identification of alternative splicing markers for breast cancer.
Cancer Res. 68:9525–9531. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Black DL: Mechanisms of alternative
pre-messenger RNA splicing. Annu Rev Biochem. 72:291–336. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen H, Zheng X, Luecke S and Green MR:
The U2AF35-related protein Urp contacts the 3′ splice site to
promote U12-type intron splicing and the second step of U2-type
intron splicing. Genes Dev. 24:2389–2394. 2010.PubMed/NCBI
|
|
27
|
Konig H, Moll J, Ponta H and Herrlich P:
Trans-acting factors regulate the expression of CD44 splice
variants. EMBO J. 15:4030–4039. 1996.
|
|
28
|
Cho S, Moon H, Yang X, et al: Validation
of trans-acting elements that promote exon 7 skipping of
SMN2 in SMN2-GFP stable cell line. Biochem Biophys Res Commun.
423:531–535. 2012.
|
|
29
|
Lee J, Zhou J, Zheng X, et al:
Identification of a novel cis-element that regulates alternative
splicing of Bcl-x pre-mRNA. Biochem Biophys Res Commun.
420:467–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Busch A and Hertel KJ: Evolution of SR
protein and hnRNP splicing regulatory factors. Wiley Interdiscip
Rev RNA. 3:1–12. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hertel KJ: Combinatorial control of exon
recognition. J Biol Chem. 283:1211–1215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Senapathy P, Shapiro MB and Harris NL:
Splice junctions, branch point sites, and exons: sequence
statistics, identification, and applications to genome project.
Methods Enzymol. 183:252–278. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen H and Green MR: RS domain-splicing
signal interactions in splicing of U12-type and U2-type introns.
Nat Struct Mol Biol. 14:597–603. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhong XY, Wang P, Han J, Rosenfeld MG and
Fu XD: SR proteins in vertical integration of gene expression from
transcription to RNA processing to translation. Mol Cell. 35:1–10.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stoilov P, Lin CH, Damoiseaux R, Nikolic J
and Black DL: A high-throughput screening strategy identifies
cardiotonic steroids as alternative splicing modulators. Proc Natl
Acad Sci USA. 105:11218–11223. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van Weering DH, Baas PD and Bos JL: A
PCR-based method for the analysis of human CD44 splice products.
PCR Methods Appl. 3:100–106. 1993.PubMed/NCBI
|
|
37
|
Cartegni L, Wang J, Zhu Z, Zhang MQ and
Krainer AR: ESEfinder: a web resource to identify exonic splicing
enhancers. Nucleic Acids Res. 31:3568–3571. 2003.PubMed/NCBI
|
|
38
|
Hernandez F, Perez M, Lucas JJ, Mata AM,
Bhat R and Avila J: Glycogen synthase kinase-3 plays a crucial role
in tau exon 10 splicing and intranuclear distribution of SC35.
Implications for Alzheimer’s disease. J Biol Chem. 279:3801–3806.
2004.PubMed/NCBI
|
|
39
|
D’Souza I and Schellenberg GD:
Determinants of 4-repeat tau expression. Coordination between
enhancing and inhibitory splicing sequences for exon 10 inclusion.
J Biol Chem. 275:17700–17709. 2000.PubMed/NCBI
|
|
40
|
Graveley BR: Sorting out the complexity of
SR protein functions. RNA. 6:1197–1211. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin S, Coutinho-Mansfield G, Wang D,
Pandit S and Fu XD: The splicing factor SC35 has an active role in
transcriptional elongation. Nat Struct Mol Biol. 15:819–826. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Qian W, Iqbal K, Grundke-Iqbal I, Gong CX
and Liu F: Splicing factor SC35 promotes tau expression through
stabilization of its mRNA. FEBS Lett. 585:875–880. 2011. View Article : Google Scholar : PubMed/NCBI
|
